Growth Metrics

BioScience Health Innovations (BHIC) Long-Term Debt Issuances (2019 - 2026)

BioScience Health Innovations has reported Long-Term Debt Issuances over the past 7 years, most recently at $748120.0 for Q1 2026.

  • Quarterly Long-Term Debt Issuances rose 26.9% to $748120.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.8 million through Mar 2026, up 104.83% year-over-year, with the annual reading at $3.0 million for FY2025, 216.36% up from the prior year.
  • Long-Term Debt Issuances was $748120.0 for Q1 2026 at BioScience Health Innovations, up from $623984.0 in the prior quarter.
  • Over five years, Long-Term Debt Issuances peaked at $802119.0 in Q2 2025 and troughed at $73727.0 in Q1 2023.
  • The 4-year median for Long-Term Debt Issuances is $270102.0 (2024), against an average of $419311.6.
  • The largest YoY upside for Long-Term Debt Issuances was 215.81% in 2024 against a maximum downside of 5.18% in 2024.
  • A 4-year view of Long-Term Debt Issuances shows it stood at $256800.0 in 2023, then grew by 5.18% to $270102.0 in 2024, then surged by 131.02% to $623984.0 in 2025, then grew by 19.89% to $748120.0 in 2026.
  • Per Business Quant, the three most recent readings for BHIC's Long-Term Debt Issuances are $748120.0 (Q1 2026), $623984.0 (Q4 2025), and $802119.0 (Q2 2025).